Evidence map›Paper›PMID 36105216›Full record

ArticleFrontiers in pharmacology2022

Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic inflammation in airway mucosa in mice.

David L Goldblatt, Gabriella Valverde Ha, Shradha Wali, Vikram V Kulkarni, Michael K Longmire, Ana M Jaramillo, Rosha P Chittuluru, Adrienne Fouts, Margarita Martinez-Moczygemba, Jonathan T Lei and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

David L GoldblattDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Gabriella Valverde HaDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Shradha WaliDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Vikram V KulkarniDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Michael K LongmireDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ana M JaramilloDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Rosha P ChittuluruDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Adrienne FoutsDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Margarita Martinez-MoczygembaDepartment of Microbial and Molecular Pathogenesis, Texas A&M Health Science Center, Houston, TX, United States.
Jonathan T LeiClinical Science and Translational Research Institute, Texas A&M Health Science Center, Houston, TX, United States.
David P HustonDepartment of Microbial and Molecular Pathogenesis, Texas A&M Health Science Center, Houston, TX, United States.
Michael J TuvimDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Burton F DickeyDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Scott E EvansDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
The University of Texas MD Anderson Cancer Center · USTexas A&M Health Science Center · USTexas A&M Health Science Center · USThe University of Texas Rio Grande Valley · US

Funding

Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumoniaR35HL144805 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2019 to 2025
$6.2M
Controlling the core airway mucin secretion machinery to prevent pathophysiologyR01HL129795 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DICKEY, BURTON F · 2015 to 2023
$3.8M
Inducible epithelial antiviral resistance to prevent asthmaDP2HL123229 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2013 to 2013
$2.4M
NHLBI NIH HHS DP2 HL123229NHLBI NIH HHS R01 HL129795NHLBI NIH HHS R35 HL144805
6 · The paper itself

Abstract

Allergic asthma is a chronic inflammatory respiratory disease associated with eosinophilic infiltration, increased mucus production, airway hyperresponsiveness, and airway remodeling. Epidemiologic data reveal that the prevalence of allergic sensitization and associated diseases has increased in the twentieth century. This has been hypothesized to be partly due to reduced contact with microbial organisms (the hygiene hypothesis) in industrialized society. Airway epithelial cells, once considered a static physical barrier between the body and the external world, are now widely recognized as immunologically active cells that can initiate, maintain, and restrain inflammatory responses, such as those that mediate allergic disease. Airway epithelial cells can sense allergens

Indexed as

allergen immunotherapyallergen toleranceallergic asthmainnate immunitylung epithelial cellstoll-like receptors

Identifiers

PMID36105216
PMCPMC9464972
OpenAlexW4293420926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.